Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | ACP1 | P24666 | 2/20 | 0.34 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.34 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21147416 | 1.00 | MEN1 (0.36) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL21146936 | 1.00 | MEN1 (0.36) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL21146945 | 1.00 | MEN1 (0.36) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL21147405 | 1.00 | MEN1 (0.36) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL21146935 | 1.00 | MEN1 (0.36) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL21147004 | 0.99 | MEN1 (0.35) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL22174943 | 0.99 | MEN1 (0.35) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL21146969 | 0.99 | MEN1 (0.35) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL21147017 | 0.99 | MEN1 (0.35) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL22174846 | 0.99 | MEN1 (0.35) | MEN1KMT2AALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11706977-B2 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-07-18 | — | — | US | disclosed |
| US-11706977-B2 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-07-18 | — | — | US | disclosed |
| US-20200212314-A1 | ORGANIC LIGHT-EMITTING DEVICE AND APPARATUS INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-07-02 | — | — | US | disclosed |
| US-20190214570-A1 | HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11706977-B2 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | CRY1, CYP1B1, CYP1A1 | MEN1 252/4885KMT2A 883/4885ALDH1A1 40/4885 |
| US-20190214570-A1 | HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | CRY1, CYP1B1, CYP1A1 | MEN1 252/4885KMT2A 883/4885ALDH1A1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.